New in Cell Reports today 20th April 2022. More Greek letters.
Lambda this time but not the #sarcov2 variants, the of proteins involved in immune regulation.

It's all Greek to me... but not #omicron.

Another letter lambda interferons the #mediators in #cells

Nasally-delivered interferon-λ can protect against infection by #SARS-CoV-2 variants including Omicron in other animals in vitro and is thought to be preferentially expressed in mucosal areas. 

Source articles are mostly under clinical trial posted on my linkedin profile - Brent Brown - click here

Type I and III Interferon binds to distinct receptors on the cell surface to activate signal transducers and activators of transcription proteins that induce expression of hundreds of antiviral stimulated genes

In vitro studies show that IFN pre-treatment can restrict SARS-CoV-2 infection in human intestinal and airway epithelia

Although type I IFNs are a potential treatment strategy for SARS-CoV-2 infection the ubiquitous expression of the IFNAR1/IFNAR2 receptor and strong, sustained pro-inflammatory responses can have pathological consequences.


Current established pathways of IFN circuitry (subject to peer review)